Clinical Trial Update: Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Above [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating safety and immunogenicity of CVI-VZV-001 for herpes zoster prevention in adults 50 and older; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• CVI-VZV-001

Snippet

Sponsor: CHA Vaccine Institute Co., Ltd. | Conditions: Vaccine-Preventable Diseases, Herpes Zoster | Phase 1 | Status: RECRUITING